Google
BIOCQ Stock Price & Analysis — Biocept Inc. (Healthcare >> Diagnostics & Research)
BIOCQ FAQ
What is BIOCQ's ROE?
Biocept Inc. reports a Return on Equity (ROE) of -13,593.79%.
What is BIOCQ's dividend yield?
Biocept Inc. offers a dividend yield of 0.00%.
What is BIOCQ's Quality Score?
Our AI rates BIOCQ's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BIOCQ?
Our AI Timing Score for BIOCQ is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BIOCQ belong to?
Biocept Inc. is classified under the Healthcare >> Diagnostics & Research sector on the NASDAQ exchange
BIOCQ AI Analysis Summary
Our AI summary for BIOCQ: Biocept Inc. (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 0.00, ROE of -13,593.79%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.00
Price
0
(0%)
Day Change
|
|
|---|
BIOCQ, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | N/A |
| PBV / Sector |
N/A / -29.69
|
| Earning Per Share | -15.05 |
| PE / Sector |
N/A / 48.18
|
| PEG or PE/Growth / Sector |
N/A / 1.64
|
| Average 1M Daily Value |
0.273960000000
GREAT
|
| Average 1W Daily Value |
0.478800000000
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
39% |
| Ability to Make Profit |
|
68% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:33 |
| Symbol | BIOCQ |
| Name | BIOCEPT INC. |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 2.63 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | N/A / 38,081.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 9955 Mesa Rim Road, San Diego, CA, United States, 92121
Phone: 858 320 8200
Website: https://biocept.com
Description: Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
